Return on equity (ROE) is the profit a company earns for every dollar of shareholder money invested in it, shown as a percentage. It is net income divided by shareholder equity, and the table shows both amounts: the profit earned and the equity it was earned on. A higher ROE means more profit per dollar of equity, but ROE also rises when equity shrinks through buybacks, dividends or losses, and it has no meaning for a company with negative equity. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
Aligos Therapeutics, Inc. roe for the quarter ending 2026-06-30 was -238.24%, a change of -165.42% year-over-year.
Aligos Therapeutics, Inc. roe for the quarter ending 2026-03-31 was -284.13%, a change of -238.39% year-over-year.
Aligos Therapeutics, Inc. roe for the quarter ending 2025-12-31 was -45.18%, a 109.98% decline year-over-year.
Aligos Therapeutics, Inc. roe for the quarter ending 2025-09-30 was -120.37%, a change of 33.25% year-over-year.
Aligos Therapeutics, Inc. roe for fiscal 2025 was -45.18%, a 109.98% decline from fiscal 2024.
Aligos Therapeutics, Inc. roe for fiscal 2024 was 452.87%, a change of 548.09% from fiscal 2023.
Aligos Therapeutics, Inc. roe for fiscal 2023 was -95.22%, a change of -2.78% from fiscal 2022.
Aligos Therapeutics, Inc. roe for fiscal 2022 was -92.44%, a change of -22.97% from fiscal 2021.